重组人血管内皮抑素联合顺铂体外干预人胃癌细胞生长的研究  

Research of recombinant human endostatin combined with cisplatin on extracorporeal intervention of growth of human gastric carcinoma cell

作　　者：邓建良[1] 谈华阳[1] 王维民[1] 周炎[1] 许春妮[1] 张国强[1] 

机构地区：[1]江苏大学附属宜兴市人民医院医院肿瘤科,江苏宜兴214200

出　　处：《实用临床医药杂志》2014年第1期42-45,共4页Journal of Clinical Medicine in Practice

基　　金：中国高校医学期刊临床专项资金(11321237)

摘　　要：目的研究重组人血管内皮抑制素(恩度)联合顺铂对人胃癌细胞株BGC823和SGC7901增殖及凋亡的影响,并探讨其抑制增殖及诱导凋亡的机制。方法采用四甲基偶氮唑盐(MTT)法检测不同浓度顺铂单药(单药组)及其与恩度联合应用(联合组)对BGC823和SGC7901细胞的增殖抑制率;采用流式细胞术分析凋亡细胞比例;采用Westernblot法分析增殖相关蛋白Ki-67及凋亡相关蛋白Bcl-2表达的变化。结果联合组对BGC823和SGC7901细胞的抑制率明显高于单药组;流式细胞术结果表明,正常对照组、单药组和联合组细胞的早期凋亡率依次增加;与单药组比较,联合组Ki-67、Bcl-2基因(蛋白)表达率显著降低。结论与顺铂单独应用相比,恩度联合顺铂对BGC823和SGC7901细胞增殖的抑制作用和诱导凋亡能力均明显增强。Objective To study the influences of recombinant human endostatin（endostar）combined with cisplatin on the proliferation and apoptosis of human gastric carcinoma cell line BGC823 and SGC7901 and to explore the related mechanism.Methods Methyl thiazolyl tetrazolium（MTT）assay was used to detect the proliferative inhibition rates of different concentrations of cisplatin（single drug group） and combination of cisplatin and endostar（combination group） on BGC823 and SGC7901.Cell apoptosis was detected by flow cytometry.Changes of proliferation-related protein Ki-67 and apoptosis-related protein Bcl-2 were analyzed by Western blot.Results The inhibition rates of BGC823 and SGC7901 in the combination group were higher than those in the single drug group. Results of Flow cytometry showed that the proportion of early apoptosis was increased in turn in normal control group, single drug group and combination group. Compared with single drug group, the expression percentage of Ki-67 and Bcl-2 mRNA（protein）decreased significantly in the combination group.Conclusion Compared with the effect of cisplatin, the combination of endostar and cisplatin is proved to be much more effective in the inhibition of the proliferation and the induction of the apoptosis of cell line BGC823 and SGC7901.

关 键 词：恩度 顺铂 胃癌 联合用药 

分 类 号：R735.2[医药卫生—肿瘤]